SCHEMBL20213014

SCHEMBL20213014

CC(C)(C)OC(=O)N1CCN(c2ncnc(C(=O)O)c2N)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.55
MAP4K4 O95819 1/20 0.51
SMARCA2 P51531 1/20 0.45
SMARCA4 P51532 1/20 0.45
PBRM1 Q86U86 1/20 0.45
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
PTPN11 Q06124 1/20 0.44
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
GBA1 P04062 2/20 0.42
GPR119 Q8TDV5 5/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
PIK3CA P42336 1/20 0.42
ACHE P22303 1/20 0.41
ADK P55263 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20213304 0.88 KIT (0.53) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL15728505 0.87 MAP4K4 (0.61) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL31737149 0.86 KIT (0.55) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL656985 0.84 HTT (0.60) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL655295 0.84 KIT (0.53) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL3885884 0.82 KIT (0.54) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL31737885 0.80 MAP4K4 (0.58) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL26107084 0.80 KIT (0.48) KITMAP4K4CKS1BSKP1SKP2
SCHEMBL14782331 0.79 MAP4K4 (0.57) KITMAP4K4SMARCA2SMARCA4PBRM1
SCHEMBL2800987 0.78 KIT (0.48) KITMAP4K4SMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723738-B2 Inhibitors of KRAS G12C mutant proteins ARAXES PHARMA LLC (US) 2020-07-28 US disclosed
US-20200062761-A1 INHIBITORS OF KRAS G12C MUTANT PROTEINS ARAXES PHARMA LLC 2020-02-27 US disclosed
US-10280172-B2 Inhibitors of KRAS G12C mutant proteins ARAXES PHARMA LLC (US) 2019-05-07 US disclosed
US-20180155348-A1 INHIBITORS OF KRAS G12C MUTANT PROTEINS ARAXES PHARMA LLC 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155348-A1 INHIBITORS OF KRAS G12C MUTANT PROTEINS KRAS, NRAS, HRAS KIT 4411/4885MAP4K4 572/4885SMARCA2 876/4885
US-10723738-B2 Inhibitors of KRAS G12C mutant proteins KRAS, NRAS, HRAS KIT 4363/4885MAP4K4 578/4885SMARCA2 868/4885
US-20200062761-A1 INHIBITORS OF KRAS G12C MUTANT PROTEINS KRAS, NRAS, HRAS KIT 4363/4885MAP4K4 578/4885SMARCA2 868/4885
US-10280172-B2 Inhibitors of KRAS G12C mutant proteins KRAS, NRAS, HRAS KIT 4411/4885MAP4K4 572/4885SMARCA2 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.